Skip to Content

Zynerba Pharmaceuticals, Inc.

Merger

  • Date:
  • 8/16/2023
  • Company Name:
  • Zynerba Pharmaceuticals, Inc.
  • Stock Symbol:
  • ZYNE
  • Company Name - Buyer:
  • Harmony Biosciences Holdings, Inc.
  • Stock Symbol - Buyer:
  • HRMY
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 8/14/2023

Case Finder

Locate any case using the tools below.

NEW YORK, August 16, 2023 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) (“Zynerba”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) (“Harmony”).

On August 14, 2023, Zynerba Corporation announced that it had entered into an agreement to be acquired by Harmony in a 200 million all-cash deal. Pursuant to the merger agreement, Harmony will commence a tender offer to acquire all outstanding shares of Zynerba for a purchase price of $1.1059 per share in cash or $60 million in the aggregate, plus one non-tradeable contingent value right (CVR) per share, representing the right to receive potential additional payments of up to $140 million in the aggregate or approximately $2.5444 in additional cash per share. The deal is expected to close by the fourth quarter of 2023.

Bragar Eagel & Squire is concerned that Zynerba's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Zynerba's stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Zynerba Pharmaceuticals. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: